

Supplemental Table 1: Patient and tumor characteristics

Subject ID	Age	Sex	Primary Site	Histology Type ¹	KRAS Status ²	PCI ³	ddPCR MAF (%)	Pre-collection treatment ⁵	Surgery ⁴	Post-collection treatment ⁵	Follow up (Months) ⁶	Status at last follow up
GI0578	62	M	Unknown	AD	WT	39	0	None	DLI	FOLFOX	3.3	Dead
GI0583	44	F	Unknown	AD-SRC	UNK	39	0	None	DL	None	1.1	Alive
GI0584	61	M	Appendix	MAD	UNK	39	0	None	DL	None	0.7	Dead
GI0585	56	F	Colon	AD	WT	13	0.075	FOLFIRI	CRS-HIPEC	FOLFOX+Bev	18.2	Dead
GI0586	67	M	Unknown	AD	UNK	39	0	None	DL	FOLFOX	19.9	Dead
GI0587	48	M	Colon	AD	WT	14	0	None	CRS-HIPEC	FOLFOX/FOLFIRI	40.3	Alive
GI0588	56	F	Unknown	AD-SRC	UNK	39	0	FOLFOX	DL	FOLFIRI+Bev	17.4	Dead
GI0605	55	M	Colon	AD-SRC	WT	0	0	FOLFOX+Bev	HIPEC	None	35.1	Alive
GI0611	52	M	Colon	MAD	G12V	33	4.350	None	DL	FOLFOX/FOLFIRI+Bev	17.2	Dead
GI0665	63	M	Appendix	GCC	WT	23	0	None	DL	None	7.6	Dead
GI0677	40	F	Colon	MAD	WT	NA	0	Partial CRS	None	FOLFOXIRI/FOLFOX	9.2	Dead
GI0694	69	F	Gallbladder	AD	UNK	NA	0	None	None	None	0.8	Dead
GI0701	61	F	Appendix	AD-GCC	G12D	23	0.512	None	CRS-HIPEC	FOLFOX+Bev	25.1	Alive
GI0734	29	M	Rectum	AD-SRC	UNK	26	0	None	DLI	FOLFOX/FOLFOXIRI+Pan	12.1	Dead
GI0764	63	M	Appendix	AD-GCC	WT	29	2.957	FOLFOX+Bev	CRS-HIPEC	None	13.3	Dead
GI0767	37	F	Jejunum	AD	G12D	13	4.680	CAPOX	CRS-HIPEC	CAPOX+Bev	19.5	Alive
GI0789	40	F	Colon	AD	WT	3	0	FOLFOX	CRS-HIPEC	FOLFIRI+Bev	17.8	Alive
GI0791	62	F	Colon	AD	G12V	2	0.101	5FU+Bev	CRS	FOLFOX+Bev	17.0	Alive
GI0794	66	M	Appendix	AD-GCC	UNK	39	0	None	DL	FOLFIRI	20.0	Alive
GI0812	51	F	Pancreas	MAD	G12D	NA	4.593	None	None	Partial CRS	4.9	Dead
GI0825	54	M	Appendix	AD-SRC	G12V	NA	4.350	FOLFOX/Cis/Reg	None	None	1.1	Dead
GI0827	68	F	Appendix	AD	UNK	27	0	CAPOX	DLI	FOLFOX	5.1	Dead
GI0828	69	M	Pancreas	MAD	UNK	8	0.327	None	DL	Gem+Pac+Ascorbate	4.3	Alive
GI0830	64	F	Pancreas	AD	UNK	NA	7.995	FOLFIRINOX/Gem+Pac	None	None	0.6	Dead
GI0863	62	M	Unknown	MAD	WT	NA	0	None	DL	FOLFOX/5FU+Bev	13.5	Alive
GI0866	67	F	Unknown	AD-SRC	WT	29	0	FOLFOX/FOLFOXIRI	DL	FOLFIRI+Pan	7.0	Alive
GI0877	59	M	Unknown	AD	G12V	NA	0.112	FOLFOX	None	None	1.1	Dead
GI0896	57	F	Appendix	AD-GCC	WT	17	0	FOLFOXIRI	DL	FOLFIRI+Bev	5.5	Alive
GI0949	56	F	Colon	AD	UNK	11	0	FOLFIRI	CRS-HIPEC	None	1.2	Alive
GI0955	40	F	Ileum	AD	WT	24	0.163	FOLFOX+Bev	CRS-HIPEC	Cap/5FU	4.6	Alive
GI0970	23	M	Rectum	AD	WT	7	0	FOLFOXIRI+Pan	CRS	FOLFOXIRI+Pan	3.9	Alive
GI1005	44	F	Colon	AD	WT	7	0	Pem	Bowel bypass	Pem/Nivo+ipi/Lar	5.2	Alive
GI1034	56	F	Unknown	AD	WT	NA	0	None	DL	FOLFOX+Bev	5.4	Alive
GI1050	60	F	Pancreas	MAD	G12D	21	2.735	None	DL	Gem+Pac/FOLFIRINOX	5.4	Dead
GI1095	54	M	Rectum	AD-SRC	WT	NA	0	FOLFOX+Pan	DL	FOLFIRI+Pan	2.5	Alive
GI1107	47	F	Colon	AD	G12V	7	0.725	FOLFOX	CRS	None	3.4	Alive
GI1130	46	F	Appendix	MAD	G12D	39	26.246	FOLFOX/FOLFIRI/HIPEC	DLI	None	1.3	Dead

1. AD: Adenocarcinoma, AD-SRC: Adenocarcinoma with signet ring cells, AD-GCC: Goblet cell adenocarcinoma, GCC: Goblet cell carcinoid, MAD: Mucinous adenocarcinoma

2. KRAS Status: Wild-type (WT), mutant (G12V, G12D), unknown (UNK)

3. Peritoneal Carcinomatosis Index (PCI) during surgical exploration. NA: Not available (for patients without surgery)

4. Surgery at the time of fluid collection: Diagnostic laparoscopy/laparotomy (DL), diverting loop ileostomy (DLI)

5. Treatment within 6 months of collection. 5FU: 5-Fluorouracil; Bev: Bevacizumab; Cap: Capecitabine; CAPOX: Capecitabine, oxaliplatin; Cis: Cisplatin; CRS: Cytoreductive surgery; FOLFIRI: 5FU, leucovorin, irinotecan; FOLFOX: 5FU, leucovorin, oxaliplatin; FOLFIRINOX: 5FU, leucovorin, irinotecan, oxaliplatin; Gem: Gemcitabine; Ipi: Ipilimumab; Lar: Larotrectinib; Nivo: Nivolumab; Pac: Nab-Paclitaxel; Pan: Panitumumab. Pem: Pembrolizumab; Reg: Regorafenib.

6. Follow up: Time interval between fluid collection and last follow-up or death.